| Document Date: 2012-04-06 17:13:06
Open Document File Size: 410,07 KBShare Result on Facebook
Company Congressional Research Services / Amgen Inc. / Milliman / / Continent Europe / / Country United States / / Currency USD / / Event FDA Phase / / IndustryTerm chemical drugs / generic chemical drugs / biological products / healthcare dollars / healthcare conditions / chemical composition / drug product / retail pharmacy / financial services / retail / overall healthcare / biotechnology-based products / casualty insurance / biosimilar applications / similar manufacturing processes / life insurance / biopharmaceutical manufacturers / actuarial and related products / healthcare / healthcare benefits / cheaper priced generic products / drug products / similar manufacturing process / treatment of certain diseases / healthcare cost management / longtime blockbuster drug products / brand-name product / manufacturing process / / MedicalCondition cancer / certain diseases / rheumatoid arthritis / Crohn’s disease / Gaucher’s disease / multiple sclerosis / breast cancer / chronic conditions / / Organization Congress / federal government / European Medicines Agency / U.S. Food and Drug Administration / FDA / World Medical Association / Medicare / / Person Pablo Fernandez / Frank Kopenski Jr. / Mark McCamish / Judith A. Johnson / / Position pharmacist / pharmacy benefit manager / pharmacist / specialist in biomedical policy / physician / senior vice president / medical affairs / 2 PharmaNet / Consulting Actuary / / Product Humira / Herceptin / Rituxan / Enbrel / Copaxone / Cerezyme / Neulasta / Remicade / Avastin / Rebif / Avonex / National Drug / / ProvinceOrState Gillian Woollet3 / / Technology biotechnology / /
SocialTag |
Milliman Client Report Prepared by: Frank Kopenski Jr., MAAA Principal and Consulting Actuary Commissioned by Amgen Inc. December 2011